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Abstract Most mammalian transcription factors (TFs) and cofactors occupy thousands of genomic
sites and modulate the expression of large gene networks to implement their biological functions. In
this study, we describe an exception to this paradigm. TRIM33 is identified here as a lineage
dependency in B cell neoplasms and is shown to perform this essential function by associating with
a single cis element. ChIP-seq analysis of TRIM33 in murine B cell leukemia revealed a preferential
association with two lineage-specific enhancers that harbor an exceptional density of motifs
recognized by the PU.1 TF. TRIM33 is recruited to these elements by PU.1, yet acts to antagonize
PU.1 function. One of the PU.1/TRIM33 co-occupied enhancers is upstream of the pro-apoptotic
gene Bim, and deleting this enhancer renders TRIM33 dispensable for leukemia cell survival. These
findings reveal an essential role for TRIM33 in preventing apoptosis in B lymphoblastic leukemia by
interfering with enhancer-mediated Bim activation.
DOI: 10.7554/eLife.06377.001
Introduction
DNA-binding transcription factors (TFs) typically recognize short 6–12 base-pair motifs, which exist at
a high frequency in mammalian genomes (Wunderlich and Mirny, 2009; Spitz and Furlong, 2012).
While chromatin restricts the accessibility of these sequences, TFs nonetheless occupy thousands of
genomic sites in any given cell type (Spitz and Furlong, 2012). As examples, MyoD has been
detected at ∼39,000 sites in primary myotubes and Pax5 at ∼20,000 sites in B cell progenitors
(Cao et al., 2010; Revilla et al., 2012). Furthermore, transcriptional cofactors (coactivators and
corepressors) are also known to occupy the mammalian genome in a generalized manner (Ram et al.,
2011). Thus, strong support exists for a model in mammalian cells in which transcriptional control is
performed by regulators that exert broad, yet highly coordinated effects on gene expression
(Wunderlich and Mirny, 2009; Spitz and Furlong, 2012). This is in stark contrast to prokaryotic
species, in which TFs can occupy as few as one or two sites in an entire genome to implement precise
transcriptional responses (Martı´nez-Antonio and Collado-Vides, 2003; Wunderlich and Mirny,
2009). Whether such a degree of gene-specificity exists among mammalian transcriptional regulators
is currently unknown.
TRIM33, also known as TIF1γ, belongs to the tripartite motif (TRIM)-containing protein family of E3
ubiquitin ligases (Venturini et al., 1999; Hatakeyama, 2011; Herquel et al., 2011). TRIM33 and its
homologs TRIM24 and TRIM28 belong to a subfamily of ubiquitously expressed TRIM proteins that
contain a tandem plant homeodomain (PHD) and bromodomain module and function as
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transcriptional cofactors (Venturini et al., 1999). One role of TRIM33 is in the TGFβ signaling
pathway, which occurs through regulation of SMAD4 mono-ubiquitination and/or by functioning as
a cofactor for the TFs SMAD2 and SMAD3 (Dupont et al., 2005, 2009; He et al., 2006; Agricola
et al., 2011). TRIM33 is also known to interact with the TF SCL/TAL1 to promote transcription
elongation of erythroid-specific genes, which may occur through the recruitment of FACT and P-TEFb
complexes (Bai et al., 2010, 2013). However, another study suggests that TRIM33 can form
repressive complexes with SCL to block transcriptional activation (Kusy et al., 2011). The PHD-
bromodomain module of TRIM33 interacts with covalently modified histone tails, which can further
stabilize TRIM33 chromatin occupancy and stimulate its E3 ligase activity (Tsai et al., 2010; Agricola
et al., 2011; Xi et al., 2011). While several studies have linked TRIM33 to transcriptional control,
a genomewide assessment of TRIM33 occupancy has yet to be performed to define the scope of its
regulatory function.
Results
RNAi screen identifies TRIM33 as a lineage dependency in cancers of
B cell origin
In an ongoing effort to identify roles for chromatin regulators as cancer dependencies, we carried out
a negative selection RNAi screen in a cell line derived from a mouse model of high risk B cell acute
lymphoblastic leukemia (B-ALL), initiated by introducing the BCR-ABL oncogene into Arf-null bone
marrow cells (Williams et al., 2006). 1,126 shRNAs targeting 259 chromatin regulators were assessed
individually for effects on the viability of B-ALL cells in culture, which led to the identification of 16
dependencies after applying stringent scoring criteria (Figure 1A and Figure 1—figure supplement 1).
The majority of these factors had been identified in a prior screen that evaluated the requirement of
chromatin regulators in MLL-AF9/NrasG12D acute myeloid leukemia (AML) (Zuber et al., 2011b),
however TRIM33 was identified here as a unique requirement in B-ALL. The six TRIM33 shRNAs used
in the screen exhibited a close correlation between knockdown efficiency and loss of B-ALL viability,
eLife digest The DNA inside every cell in a human body is the same, and yet the activities that
occur within different types of cells can vary greatly. White blood cells, for example, are different
from skin cells or liver cells because different genes are active in each type of cell. Molecules called
transcription factors and transcriptional cofactors associate with specific DNA sequences to control
the activity of nearby genes. It is common for a single transcription factor or cofactor to bind to
thousands of sites across the DNA of any cell.
In humans, our immune systems protect us against infectious diseases and from malfunctioning
cells that could become cancerous. White blood cells called B cells provide part of this immune
defense. These cells help to identify invading bacteria and viruses, and can also develop into memory
cells that help the immune system to rapidly recognize, respond to and eliminate a disease if it is re-
encountered.
Immature B cells—also known as B lymphoblasts—mature within bone marrow. If any problem
occurs in a cell as it matures, that cell is usually programmed to self-destruct in a process called
apoptosis. If these cells are not destroyed, they can accumulate in the bone marrow and prevent the
production of other immune cells. This leads to a type of cancer called acute lymphoblastic leukemia.
Wang et al. now reveal that TRIM33—a protein that B-lymphoid leukemia cells need to survive—is
a transcriptional cofactor that prevents apoptosis. Furthermore, unlike other known transcription
factors and cofactors in mammals, TRIM33 binds to an exceedingly small number of sites across the
DNA of B cells. In fact, the cancer cell’s dependency on the protein is due to TRIM33 associating with
just a single binding site.
The role of TRIM33 in B cell leukemia also has potential therapeutic implications. Although it is
found in cells throughout the body, Wang et al. found that inhibiting TRIM33 in mice resulted in lower
numbers of B cells being produced, but did not affect other tissues. Developing drugs that prevent
TRIM33 from working could therefore provide new options for treating leukemia.
DOI: 10.7554/eLife.06377.002
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Figure 1. RNAi screen identifies TRIM33 as a lineage dependency in cancers of B cell origin. (A) Negative selection shRNA screen targeting chromatin
regulators in murine B cell acute lymphoblastic leukemia (B-ALL). shRNAs are rank ordered by the fold-change in GFP positivity over 10 days in culture,
which represents a competition-based assay in which loss of GFP positivity reflects shRNA-postive cells becoming outcompeted by shRNA-negative cells.
(B–E) Competition-based assays and Western blotting to evaluate the effect of TRIM33 shRNAs on B-ALL, 38B9, acute myeloid leukemia (AML), or T-cell
acute lymphoblastic leukemia (T-ALL) cells. GFP percentages are normalized to day 2 measurements. Results are the average of three biological
replicates. (F) Annexin V/DAPI staining following transduction of B-ALL cells with the indicated MLS shRNAs on day 3 post-transduction. Representative
experiment of three biological replicates is shown. (G) shRNA transgenic mouse strategy. TRE: tet(doxycycline) response element; rtTA-M2: reverse tet
transactivator M2 variant (tet-on). (H) Western blotting performed of indicated tissue lysates prepared from mice treated with dox for 4 weeks.
Figure 1. continued on next page
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suggesting on-target effects (Figure 1A,B). Furthermore, a v-Abl transformed B cell progenitor line,
38B9 (Alt et al., 1984), and several human B cell cancer lines were also sensitive to TRIM33
knockdown (Figure 1C and Figure 1—figure supplement 1). In contrast, TRIM33 knockdown led to
negligible effects on the viability of MLL-AF9/NrasG12D AML and Notch-mutant T-cell acute
lymphoblastic leukemia (T-ALL) (Figure 1D,E). Upon knockdown of TRIM33, B-ALL cells underwent
apoptosis, as shown by Annexin V/DAPI staining (Figure 1F). Taken together, these observations
suggest that TRIM33 is essential for the survival of neoplastic B cells.
To compare the TRIM33 requirement in B-ALL with its role in normal tissues, we derived transgenic
mice in which a TRIM33 shRNA was expressed from a doxycycline (dox)-regulated promoter
(Figure 1G) (Premsrirut et al., 2011). When crossed with mice that express rtTA-M2 from the
ROSA26 promoter, animals exhibited dox-dependent suppression of TRIM33 in multiple tissues
(Figure 1G,H and Figure 1—figure supplement 2). Flow cytometry analysis of the bone marrow and
spleen following 1 or 4 weeks of dox administration revealed a selective loss of CD19+ and B220+ B
lymphoid cells in TRIM33-deficient animals, while erythroid, myeloid, and T lymphoid populations
remained intact or even increased in relative abundance (Figures 1I,J). Taking advantage of the
reversibility of the dox-regulated shRNA system, we found that B cell production recovered fully in
TRIM33-deficient mice upon restoring TRIM33 expression (Figure 1—figure supplement 2). Notably,
TRIM33 knockdown led to negligible effects on the histological appearance of colon, liver, thymus,
and pancreatic tissues and led to no significant changes in animal weight (Figure 1—figure
supplement 2). Collectively, these findings suggest that B lymphoid cells are uniquely sensitive to
TRIM33 inhibition, thus implicating TRIM33 as a lineage dependency in cancers of B cell origin. These
results are in agreement with the prior characterization of Trim33−/−mice, which were found to exhibit
a B lymphocyte deficiency and an expansion of myeloid cells (Aucagne et al., 2011; Kusy et al., 2011;
Bai et al., 2013).
TRIM33 preferentially associates with two lineage-specific enhancers in
B lymphoblastic leukemia cells
We next evaluated the mechanism underlying the essential TRIM33 function in B cell neoplasms. To
this end, we performed RNA-seq analysis in B-ALL cells following 3 or 4 days of TRIM33 knockdown.
This analysis revealed a distribution of gene expression changes, however, we noted that Bim and
Atp1b3 were the two most upregulated genes upon TRIM33 depletion (Figure 2A). To evaluate
whether any of these mRNA changes were due to direct regulation, we performed ChIP-seq analysis
in B-ALL cells to evaluate the genomic localization of TRIM33 and various histone modifications that
annotate active promoter and enhancer regions. Remarkably, the two strongest sites of TRIM33
enrichment in B-ALL were located 117 kb upstream of Bim (in an intron of a non-expressed gene
Acoxl) and at a site 35 kb upstream of Atp1b (Figure 2B–D). The other gene expression changes
incurred upon TRIM33 knockdown did not correlate with its genomic occupancy (data not shown),
suggesting they might be an indirect effect of B-ALL cells initiating an apoptotic response. The
TRIM33-occupied regions upstream of Bim and Atp1b3 were enriched for H3K27 acetylation but not
for H3K4 tri-methylation, suggesting that these elements are active enhancers (Rada-Iglesias et al.,
2011) (Figure 2C,D). We also observed TRIM33 occupancy at these same two regions in 38B9, AML,
and in whole spleen, but not in T-ALL (Figure 2—figure supplements 1, 2). A striking attribute of the
genomewide pattern of TRIM33 occupancy was its strong bias for a small number of locations, with
Figure 1. Continued
Representative experiment of three biological replicates is shown. (I–J) Flow cytometry analysis using the indicated antibody stainings of whole bone
marrow or spleen. B220 and Cd19: B lymphoid, Ter119: erythroid, Gr1 and Mac1: myeloid, Cd3: T lymphoid. Gating was performed on GFP+/shRNA+ cells
prior to quantifying marker positivity. The GFP+ percentage in bone marrow was ∼75% and in the spleen was ∼15%. Mice were administered dox for 1
week or 4 weeks, with both timepoints giving similar results. Results shown are the average 4 or 5 mice. All error bars in this figure represent S.E.M.
DOI: 10.7554/eLife.06377.003
The following figure supplements are available for figure 1:
Figure supplement 1. Hits identified in the shRNA screen and validation experiments in human cell lines.
DOI: 10.7554/eLife.06377.004
Figure supplement 2. Additional analysis of TRIM33 shRNA transgenic mice.
DOI: 10.7554/eLife.06377.005
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Figure 2. TRIM33 preferentially associates with two lineage-specific enhancers in B lymphoblastic leukemia cells. (A) RNA-seq analysis of B-ALL cells
transduced with shTRIM33.1271. shRNA+/GFP+ cells were sorted on day 3 or 4 post-infection. Plotted is the average fold-change in mRNA level of two
independent biological replicates. (B) Ranking of TRIM33 occupied sites based on average tag counts obtained from B-ALL ChIP-seq analysis. The 31
regions shown represent the significant reproducible peaks identified in two independent biological replicates. (C–F) B-ALL ChIP-seq occupancy profiles
using the indicated antibodies. The y-axis reflects the number of cumulative tag counts in the vicinity of each region. Validated transcript models from the
mm9 genome assembly are depicted below.
DOI: 10.7554/eLife.06377.006
The following figure supplements are available for figure 2:
Figure 2. continued on next page
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lower levels of enrichment at other sites across the genome (Figure 2E,F, and Figure 2—figure
supplements 3, 4). This analysis suggests that TRIM33 is concentrated at a small number of sites in
the B-ALL genome, with two of these regions correlating with a repressive effect on the expression of
nearby Atp1b3 and Bim genes.
TRIM33 preferentially associates with enhancers harboring an
exceptional density of the PU.1 TF
We next pursued the mechanism underlying the profound accumulation of TRIM33 at the Bim –117
and Atp1b3 –35 regions in B-ALL. Using the FIMO motif analysis tool (Grant et al., 2011), we found
that both of these regions possessed a high density of sequence motifs recognized by PU.1 (17
instances at Bim –117 and 14 instances at Atp1b3 –35), which is an essential hematopoietic TF
expressed in B lymphoid and myeloid lineages (Scott et al., 1994). In contrast, we observed a much
lower density of motifs for other TFs involved in B cell specific transcriptional regulation (E2A, EBF1, or
PAX5) (Figure 3A,B). Since TRIM33 has been shown previously to interact with PU.1 (Kusy et al.,
2011), we investigated whether PU.1 promotes TRIM33 recruitment to these regions. ChIP-seq
analysis of PU.1 in B-ALL confirmed its association with Bim –117 and Atp1b3 –35, as well as with more
than 2600 other genomic sites (Figure 2C,D and Figure 3—figure supplement 1). Remarkably, Bim
–117 and Atp1b3 –35 regions are outliers when compared to other PU.1-occupied sites with regard to
the overall density of PU.1 recognition motifs and the overall level of PU.1 enrichment (Figure 3C and
Figure 3—figure supplement 1). The level of the active enhancer chromatin mark, H3K27ac, is not
skewed in a similar manner towards these two locations, indicating that these regions are not super-
enhancers that exhibit high levels of all regulators (Figure 3—figure supplement 1) (Hnisz et al.,
2013). Using ChIP-qPCR, we also confirmed PU.1 occupancy at these two regions in 38B9 and AML
cells, but not in T-ALL (Figure 3—figure supplement 2).
These findings raised the possibility that an exceptional density of PU.1 at these two sites might
serve as the trigger for TRIM33 recruitment. To evaluate this, we used shRNAs to derive
PU.1-deficient B-ALL cells, which displayed normal proliferation and viability (Figure 3—figure
supplement 3, data not shown). We found that PU.1 knockdown led to a significant loss of TRIM33
occupancy at Bim and Atp1b3 in proportion to the loss of PU.1 (Figure 3D,E, and Figure 3—figure
supplement 3). PU.1-deficient B-ALL cells also harbored reduced H3K27ac at Bim –117 and reduced
Bim mRNA levels, suggesting that PU.1 is responsible for maintaining this enhancer in an active state
while, paradoxically, also facilitating TRIM33 recruitment (Figure 3F and Figure 3—figure
supplement 3). Collectively, these results suggest that a high density of PU.1 underlies the skewed
distribution of TRIM33 genomic occupancy observed in B-ALL.
TRIM33 antagonizes PU.1 function to promote B-ALL cell survival
Since PU.1 and TRIM33 appear to have opposing effects on Bim expression (Figure 2A and
Figure 3—figure supplement 3), we next evaluated how TRIM33 regulates the function of PU.1 at
their co-occupied sites. Interestingly, knockdown of TRIM33 led to an increase in PU.1 occupancy and
H3K27 acetylation at Bim –117, suggesting that TRIM33 antagonizes PU.1 binding to DNA and
suppresses enhancer activity, consistent with prior findings (Kusy et al., 2011) (Figure 3G–I). This
result is significant, since Bim –117 is already heavily enriched for PU.1 in B-ALL cells, but PU.1
occupancy becomes even greater when TRIM33 is suppressed. Consistent with the functional
importance of PU.1 antagonism by TRIM33, we found that knockdown of PU.1 resulted in a reduced
Figure 2. Continued
Figure supplement 1. (A–B) TRIM33 ChIP-seq occupancy profiles at the Bim locus (A) and the Atp1b3 locus (B) in the indicated cell types.
DOI: 10.7554/eLife.06377.007
Figure supplement 2. Trim33 ChIP-qPCR analysis in various cell lines.
DOI: 10.7554/eLife.06377.008
Figure supplement 3. (A–D) Comparison of two independent TRIM33 ChIP-seq biological replicates in B-ALL.
DOI: 10.7554/eLife.06377.009
Figure supplement 4. TRIM33 ChIP-seq analysis in 38B9, AML, and T-ALL.
DOI: 10.7554/eLife.06377.010
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Figure 3. TRIM33 is recruited by PU.1 to select enhancers and antagonizes PU.1 function to promote B-ALL survival. (A) Motif analysis using the FIMO/
MEME algorithm. The table indicates the number of motif matches in each sequence interval. (B) Schematic diagram of PU.1 motif (MA0080.3) locations
across the indicated cis elements. (C) Analysis of PU.1 motifs (MA0080.3) counts at all of the 2682 PU.1 peaks identified by ChIP-seq. (D–I) ChIP-qPCR
analysis at the indicated locations of the Bim locus in B-ALL. Labels refer to the kilobase distance relative to the Bim TSS. For TRIM33 knockdown
experiments (G–I), both shRen and shTRIM33 were introduced into B-ALL cells harboring a Bim shRNA. Plotted is the average of three biological
replicates. (J) Competition-based assay evaluating effect of a PU.1 shRNA on the sensitivity of B-ALL cells to TRIM33 knockdown. shRen or shPU1 linked to
GFP were introduced first into B-ALL cells and then were subsequently transduced with shTRIM33 or shRen linked to mCherry. The GFP/mCherry double
Figure 3. continued on next page
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sensitivity of B-ALL and 38B9 cells to the lethal effects of TRIM33 knockdown (Figure 3J and
Figure 3—figure supplement 4). Collectively, these observations suggest that TRIM33 antagonizes
PU.1-dependent enhancer activation as part of its essential function in B lymphoblastic leukemia.
TRIM33 occupancy at a single Bim enhancer accounts for its essential
function in B-ALL
Bim encodes a BH3-only domain protein with a well-established pro-apoptotic function (Willis and
Adams, 2005). Therefore, we considered whether repression of Bim is the essential role of TRIM33 in
B-ALL. For this purpose we suppressed Bim using shRNAs and evaluated how this influenced the
sensitivity of cells to TRIM33 knockdown (Figure 4A,B). Notably, Bim-deficient B-ALL cells were
completely resistant to the apoptotic effects of TRIM33 shRNAs, indicating that Bim is the critical
downstream repression target of TRIM33 to maintain cell viability (Figure 4B). In contrast, Atp1b3
knockdown did not alter the sensitivity of B-ALL to TRIM33 suppression (data not shown). To further
evaluate whether the essential function of TRIM33 is due to its occupancy at the −117 region, we
employed CRISPR-Cas9 to delete this element (Cong et al., 2013; Mali et al., 2013) (Figure 4C,D).
Similar to the effects observed upon Bim knockdown, three independent B-ALL clones harboring
a homozygous deletion of the −117 element did not require TRIM33 for viability (Figure 4E). Bim
knockdown and the deletion of the Bim –117 region also rendered 38B9 cells resistant to the lethal
effects of TRIM33 suppression (Figure 4—figure supplement 1). This indicates that a single genomic
binding site at the Bim locus accounts for the entire TRIM33 requirement in preventing B-ALL
apoptosis.
While both B lymphoid and myeloid leukemia cells harbor PU.1 and TRIM33 at the Bim –117 region,
it is important to note that knockdown of TRIM33 in AML does not result in apoptosis or Bim
upregulation (Figure 1D and Figure 4—figure supplement 2). ChIP-seq analysis of H3K27ac revealed
that AML cells possess a large cluster of active enhancers located 66 kb upstream of Bim, which is not
observed in B-ALL (Figure 4—figure supplement 2). Importantly, the level of H3K27ac at this
AML-specific enhancer cluster is much greater than that observed at the −117 region. This leads us to
speculate that the AML-specific enhancers at the −66 kb region might be the dominant regulatory
elements at the Bim locus in this cell type. The overall strength of these enhancers in AML may diminish
the functional significance of the −117 element, thereby rendering TRIM33 dispensable for AML survival.
Discussion
Here we provide evidence that TRIM33 prevents apoptosis in murine B-ALL cells by blocking
enhancer-mediated Bim activation. The role of TRIM33 as a negative regulator of enhancer activity is
reminiscent of LSD1, a histone demethylase that has been shown previously to suppress active
enhancers during embryonic stem (ES) cell differentiation (Whyte et al., 2012). However, a key
distinction we make here is that LSD1 suppresses thousands of enhancers in ES cells, while TRIM33
preferentially accumulates at a small number of regulatory elements in the B-ALL genome. We trace
this unusual enhancer selectivity of TRIM33 in B-ALL to the density of PU.1, a TF which has been shown
previously to associate with TRIM33 (Kusy et al., 2011). This binding interaction is likely to be
cooperative on motif-rich DNA elements, which would account for the biased accumulation of TRIM33
Figure 3. Continued
positive population was measured over time. Results are normalized to day 2 measurements. Plotted is the average of three biological replicates. All error
bars in this figure represent S.E.M.
DOI: 10.7554/eLife.06377.011
The following figure supplements are available for figure 3:
Figure supplement 1. (A–B) Ranked ordering of PU.1 and H3K27 acetylation peaks identified using ChIP-seq analysis in B-ALL.
DOI: 10.7554/eLife.06377.012
Figure supplement 2. (A–B) PU.1 ChIP-qPCR analysis at the indicated locations of Bim (A) and Atp1b3 (B) loci in 38B9, AML, and T-ALL.
DOI: 10.7554/eLife.06377.013
Figure supplement 3. Additional PU.1 knockdown experiments.
DOI: 10.7554/eLife.06377.014
Figure supplement 4. Competition-based assay evaluating effect of a PU.1 shRNA on the sensitivity of 38B9 cells to TRIM33 knockdown.
DOI: 10.7554/eLife.06377.015
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at enhancers harboring an exceptional PU.1 density. Our ChIP-seq analysis of TRIM33 in myeloid, B
lymphoid, and T lymphoid leukemias suggests that other TFs are also likely to recruit TRIM33, such as
TCF3/E2A (Figure 2—figure supplement 4). To our knowledge, TRIM33 is the first example of
Figure 4. TRIM33 occupancy at a single Bim enhancer accounts for its essential function in B-ALL. (A) Western blot performed on extracts prepared from
B-ALL following transduction with the indicated shRNAs. Labeled are two of the known Bim isoforms. TRIM33.3905 shRNA was used. (B) Competition-
based assay evaluating the effect of Bim knockdown on the sensitivity of B-ALL cells to TRIM33 knockdown. shRen or shBim linked to GFP were introduced
first into B-ALL cells and then were subsequently transduced with shTRIM33 or shRen linked to mCherry. The GFP/mCherry double positive population
was measured over time. Results are normalized to day 2 measurements. Plotted is the average of three biological replicates. (C) Experimental design for
generating a homozygous deletion of the Bim –117 region using CRISPR-Cas9. sgRNAs were designed to cut at locations flanking the TRIM33 binding site
to delete the intervening 1.4 kb. Location of PCR primers used for genotyping are indicated. (D) Genotyping PCR to track the CRISPR-based deletion.
Parental refers to Cas9+ B-ALL cells. +sgRNAs refers to Cas9+ B-ALL cells co-transduced with two sgRNAs targeting the Bim –117 element linked to
mCherry reporters. Three clonal lines were derived by limiting dilution. (E) Competition-based assay evaluating the effect of the Bim –117 deletion on the
sensitivity to TRIM33 knockdown. B-ALL cells were transduced with indicated shRNAs linked to GFP reporters. TRIM33.3905 shRNA was used. Results are
normalized to day 2 measurements. Plotted is the average of three biological replicates. All error bars in this figure represent S.E.M.
DOI: 10.7554/eLife.06377.016
The following figure supplements are available for figure 4:
Figure supplement 1. Additional experiments evaluating the role of Bim in 38B9 cells.
DOI: 10.7554/eLife.06377.017
Figure supplement 2. Additional experiments evaluating the role of TRIM33 in AML and T-ALL.
DOI: 10.7554/eLife.06377.018
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a mammalian transcriptional regulator that performs an essential function through a single genomic
binding site.
The selective occupancy of TRIM33 within the active enhancer landscape may account for the minimal
phenotypes observed in TRIM33-deficient mice. This is in contrast to the effects of suppressing BRD4,
a more general cofactor that is essential for the maintenance of many cancer types and for the
homeostasis of several normal tissues (Bolden et al., 2014; Shi and Vakoc, 2014). Remarkably, it is the
localization of TRIM33 to one lineage-specific enhancer upstream of Bim that renders B-ALL cells
hypersensitive to loss of TRIM33. The similar sensitivity of normal and transformed B cells to TRIM33
inhibition implies that the regulatory mechanisms defined here in B cell leukemia are likely to have
evolved to control normal B cell development. Interestingly, Bim is upregulated as a means to eliminate
auto-reactive B cells and to prevent autoimmune disease, suggesting a rationale for precise modulation
of enhancer activity at the Bim locus by TRIM33 to regulate adaptive immunity (Bouillet et al., 1999;
Enders et al., 2003).
In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20
antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune
disease (Coiffier et al., 2002; Edwards et al., 2004). Hence, our findings also implicate TRIM33 as
a promising therapeutic target, since one of the major phenotypic abnormalities in mice experiencing
systemic TRIM33 inhibition is a selective and reversible B lymphocyte deficiency. Targeting of TRIM33
is particularly attractive since other bromodomain modules (e.g., BRD4) have proven to be amenable
to direct chemical inhibition (Prinjha et al., 2012). However, we observe a modest expansion of
myeloid cells upon short durations of TRIM33 suppression in vivo and Trim33−/− mice have been
shown to develop chronic myelomonocytic leukemia (Aucagne et al., 2011). Thus, long-term
inhibition of TRIM33 might have pro-tumorigenic effects in certain tissues. Nonetheless, our findings
justify consideration of TRIM33-inhibition as a therapeutic approach in B cell neoplasms, which would
be expected to unleash an apoptosis-promoting enhancer element.
Materials and methods
Plasmids
For competition-based assays in murine cells, the LMN-GFP or LMN-mCherry shRNA retroviral vector
were used (MSCV-miR30-shRNA-PGKp-NeoR-IRES-GFP/mCherry). When drug selection was re-
quired, some experiments were performed using MLP-GFP (MSCV-miR30-shRNA-PGKp-PuroR-IRES-
GFP). For Annexin V experiments, the MLS vector was used (MSCV-miR30-shRNA-SV40p-GFP) to
obtain a higher infection efficiency. For competition assays in human cell lines, the MLS-E vector was
used (MSCV-miRE-shRNA-SV40p-GFP) (Fellmann et al., 2013). All of the cloning procedures were
performed using the In-Fusion cloning system (#638909; Clontech, Mountain View, CA).
Cell culture and virus production
Murine B-ALL (driven by BCR-ABL and p19Arf inactivation) (Williams et al., 2006) and 38B9 (Alt et al.,
1984) were cultured in RPMI supplemented with 10% fetal bovine serum (FBS), 1% penicillin/
streptomycin, and 0.055 mM 2-Mercaptoethanol. Derivation of MLL-AF9/NrasG12D AML cells is
described in Zuber et al. (2011a). The T-ALL cell line was provided by I Aifantis (NYU) and was
derived from TAL transgenic/HEB heterozygous mice with an acquired truncation of Notch1. Murine
AML and T-ALL cells and human REH, SU-DHL, MM1S, and JURKAT cell lines were cultured in RPMI/
10% FBS/1% penicillin/streptomycin.
The retroviral and lentiviral packaging cells Ecotropic Plat-E cells (Morita et al., 2000) and
HEK293T cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.
All retroviral packaging was performed according to established protocols (Morita et al., 2000). Virus
was collected 48–72 hr post-transfection.
Negative selection RNAi screen
A previously described LMN shRNA library targeting chromatin regulatory proteins was used (Zuber
et al., 2011b). Additional shRNAs were included in the library to allow comprehensive targeting of all
bromodomain-containing proteins. shRNA plasmids from this library were arrayed individually in 96
well plates at 50 ng/μl for retrovirus preparation using Ecotropic Plat-E cells as described (Morita
et al., 2000). Viral transduction of B-ALL cells was also performed in 96 well plates, followed by
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flow-cytometry-based measurement of GFP positivity using a Guava Easycyte instrument (Millipore,
Billerica, MA). Measurements were performed on day 2 and day 12 post-transduction. Renilla and
Rpa3 control shRNAs were included with each 96 well plate as negative and positive controls,
respectively. If an shRNA was introduced into B-ALL cells with a day 2 GFP percentage below 5%, this
sample was discarded from the screen. The lower limit on GFP% measurements on day 12 was
arbitrarily set at 0.2%. A single instance of Renilla and Rpa3 control shRNAs are included in the screen
histogram shown in Figure 1A. The screen data can be found in Supplementary file 1.
Competition assay to measure cellular effects of shRNA
To evaluate the effect of shRNAs on murine cell proliferation (e.g., in Figure 1A–E), cultures were
retrovirally transduced with the indicated LMN-GFP shRNA vectors, followed by measurement of the
GFP percentages over a time course post-infection using a Guava Easycyte flow cytometer. For
double shRNA competition-based assays (e.g., Figures 3J, 4B), cells were first transduced with MLP-
GFP (Ren, Bim, or PU.1 shRNA) and then were selected with puromycin (1 μg/ml). Cells were
subsequently transduced with LMN-mCherry (Ren or TRIM33 shRNAs) and double GFP/mCherry
positivity was tracked using a BD LSR2 flow cytometer. For human competition assays in
Figure 1—figure supplement 1, the MLS-E vector was used and GFP was tracked using a Guava
Easycyte instrument. shRNA sequences can be found in Supplementary file 2.
Annexin V staining for cell death analysis
In order to quantify the cell death effect induced by Renilla or TRIM33 shRNAs, B-ALL cells were
transduced at a high efficiency (>95% GFP) using the MLS-GFP vector. After 3 days post-infection,
cells were spun down, washed with PBS and resuspended in 1× binding buffer and incubated with
APC Annexin V antibody (as described by manufacturer protocol, #550475; BD Pharmingen, San
Diego, CA) and DAPI, followed by BD LSRII flow cytometry analysis. GFP gating was not performed.
The three independent TRIM33 shRNAs revealed similar results. The data analysis was performed
using Flowjo software.
Transgenic animal studies
All experimental mouse procedures were approved by the Cold Spring Harbor Animal Care and Use
Committee. Renilla and TRIM33 shRNA targeted ES cells were derived by Mirimus (Cold Spring
Harbor, NY) as described (Premsrirut et al., 2011; Dow et al., 2012), using site-specific integration of
the shRNA cassette into the Col1a1 locus of KH2 ES cells (Beard et al., 2006). 8–10 week old mice
heterozygous for alleles of shRen.713 or shTRIM33 and homozygous for ROSA26-rtTA-M2 alleles
were treated with dox drinking water (2 mg/ml doxycycline and 2% sucrose) and dox food (625 mg/
kg) for 7 or 28 days. Fluorescent markers (eGFP for shRenilla and TurboGFP for shTRIM33) were
indicators of shRNA-expressing cells following doxycycline treatment. The animal health and body
weight were monitored during the time course of experiments. Primers used for genotyping can be
found in Supplementary file 2.
To measure the impact of TRIM33 knockdown on hematopoietic lineages, bone marrow and spleen
tissues were harvested from 8–10 week old transgenic mice following the administration of dox for 7 or
28 days. A single cell suspension of harvested samples was treated with ACK buffer (150 mM NH4Cl,
10 mM KHCO3, 0.1 mM EDTA) to lyse the red blood cells. The sample was then stained with
hematopoietic lineage marker antibodies (1:200) in FACS buffer (1× PBS with 5% FBS and 0.05% NaN3)
for 30 min and then subjected to BD LSRII flow cytometry analysis. Gating was performed on live cells
(FSC/SSC) and on GFP+ cells prior to quantifying marker positivity. The GFP percentage in total bone
marrow was approximately 75% on dox for shRen and shTRIM33 mice. The GFP percentage in the total
spleen was approximately 15% for shTRIM33 and shRen mice on dox. This heterogeneity in GFP
expression in these different tissues requires GFP gating to accurately define hematopoietic
phenotypes using flow cytometry. The data analysis was performed using Flowjo software.
To evaluate the reversibility of the TRIM33 knockdown phenotype in bone marrow B lymphoid cell,
animals were placed on dox for 7 days and a second cohort was placed on dox for 7 days followed by
removal of dox for 21 additional days. B220 and Cd19 marker staining was performed as described
above, but the GFP marker was not gated upon since GFP expression is extinguished upon removing
dox. This accounts for the weaker B cell phenotype in this 7 day dox treatment from the findings
presented in Figure 1I, in which GFP gating was performed.
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For immunohistochemistry analysis of TRIM33 expression, transgenic mice were maintained on dox
for 28 days. Mouse tissues were fixed overnight in 10% neutral buffered formalin and then washed
with PBS. Samples were then processed using Shandon Excelsior Tissue processor and embedded in
paraffin, 6 micron sections were then mounted onto VWR Superfrost Plus slides.
Western blotting
For western blotting, whole cell lysates were prepared by direct lysis using SDS-PAGE sample buffer
and about 50,000 cell equivalents were loaded into each lane. Samples were then separated by
SDS-PAGE electrophoresis and transferred to nitrocellulose for detection using antibodies. For
western blotting of mouse tissues, samples were harvested and lysed in RIPA buffer (25 mM Tris-HCl
pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS) using a dounce
homogenizer, then briefly sonicated and incubated on ice for 15 min. Pellets were spun down and
the supernatant was collected and quantified using a Bradford assay. 20 μg of protein were loaded
into each gel lane.
Immunohistochemistry
Deparaffinization of samples was done with Xylene (2 × 10 min) followed by ethanol rehydration
(100%-2 × 5 min, 95% and 75% 2 min each) and washed in distilled water. 3% Hydrogen Peroxide
was used for blocking endogenous peroxidase, followed by another wash. Antigen retrieval was
done with Citrate buffer in an Electric Pressure Cooker then washed in TBS. Samples were then
blocked with 5%NHS, 1%BSA in TBS for 1 hr at room temperature and incubated with TRIM33
antibody (1:500/1:1000) overnight at 4˚C. Followed by washing with TBS and incubated with Vector
mp-7401 anti-rabbit secondary antibody for 30 min and then washed again. Slides were then
incubated with Vector ImmPACT DAB, SK-4105 for 3 min and then rinsed in water. Counterstaining
was performed with Hematoxylin and coverslipping was performed with Surgipath mounting
medium prior to analysis.
Chromatin immunoprecipitation
Cells were crosslinked with 1% formaldehyde for 20 min at room temperature and then quenched with
0.125 M glycine. Samples were sonicated and incubated with 5 μg of antibody overnight and then
precipitated using Protein A Dynabeads (cat #10002Dl; Life Technologies, Grand Island, NY). For
TRIM33/PU.1 ChIP in B-ALL, 50 million cells were used for each ChIP conditions with 5 μg antibody.
For histone modification ChIP experiments in B-ALL, 20 million cells were used for each ChIP
conditions with 2 μg antibody. For whole spleen ChIP, 6–8 week old mice were sacrificed and
a suspension of 30 million splenocytes was prepared for ChIP with 5 μg antibody. ChIP-qPCR was
performed on the reverse crosslinked DNA samples as previously described (Steger et al., 2008). All
of the results were quantified by qPCR using SYBR green (ABI, Grand Island, NY) on an ABI 7900HT.
Each IP signal was quantified based on an input standard curve dilution series of the pre-
immunoprecipitated genomic DNA (IP/Input) to normalize for the differences of total amount of cells
subjected for ChIP and for the different amplification efficiencies of various primer sets.
RT-qPCR analysis
Total RNA was extracted from cells using Trizol reagent according to the manufacturer’s instructions.
Upon isolating RNA, DNase I was treated to eliminate contaminating genomic DNA. For cDNA
synthesis, Q-Script cDNA SuperMix (Quanta BioScience, Gaithersburg, MD) was used. All results were
quantified by qPCR performed using SYBR green (ABI) on an ABI 7900HT using the delta Ct method
using Gapdh as a control gene.
All ChIP and RT-qPCR primers used in this study can be found in Supplementary file 2.
ChIP-seq and RNA-seq library preparation
ChIP DNA was purified using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA) and ChIP-Seq
libraries were constructed using TruSeq ChIP Sample Prep Kit (Illumina) following the manufac-
turer’s instructions. The quality of each library was determined by Bioanalyzer analysis using the
High Sensitivity chip (Agilent). Two independent biological replicates were performed for each
ChIP-seq experiment. Barcoded libraries were sequenced in a multiplexed fashion with two to six
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libraries at equal molar ratio, with single end reads of 50 bases. For RNA-seq, total RNA was
extracted using Trizol reagent (Invitrogen, Carlsbad, CA). Libraries were constructed using the
TruSeq sample Prep Kit V2 (Illumina, San Diego, CA) according to the manufacturer’s instructions.
DNA libraries were sequenced using an Illumina HiSeq 2000 platform.
RNA-seq analysis
The obtained reads were trimmed into 28 base reads corresponding to 9th to 36th position from the
5′ ends of the reads. These reads were mapped to the mouse genome (mm9) using Tophat software
allowing no mismatch, then differentially expressed genes were analyzed by using Cuffdiff software.
During this step, structural RNAs (e.g., ribosomal or mitochondrial RNA) were masked. To calculate
relative fold change to control, only genes with expression cutoff above 5 reads per million per
kilobase (RPKM) and OK test status were considered. Average RPKM from two biological replicates of
each control (Ren) and TRIM33 shRNA expressed samples was then used to calculate fold change with
log2 scale.
ChIP-seq analysis
The sequence reads were of 36 or 50 bp in length and mapped to the reference murine genome
assembly NCBI37/mm9 using Bowtie. Alignments were performed using the following criteria: -m1,
-v2. To identify ChIP-Seq peaks, we used the MACS version 1.4.0 beta (Model based Analysis of
ChIP-Seq) peak finding algorithm by using a p value threshold of enrichment of 1e-5 as a cut-off.
For AML, 38B9, and T-ALL, we also implemented a 10-fold IP/Input enrichment ratio as a filtering
criteria. To identify reproducibly enriched regions of TRIM33 ChIP-Seq from two biological
replicates, called peaks from MACS were compared and intersected. If the peaks showed at least
1 bp overlap between replicates, they were considered as reproducible. To calculate average tag
counts from reproducible peaks, tag counts were normalized to total mapped reads, and further
ranked by tag counts.
All ChIP-seq and RNA-seq data from this study can be found at the GEO accession super-series
GSE66234.
FIMO/MEME motif analysis
Sequence coordinates from TRIM33 peak calling using MACS were used to obtain sequences of Bim-
117 and Atp1b3 regions. Analysis was performed at the FIMO/MEME website: http://meme.nbcr.net/
meme/tools/fimo using a p-value output threshold of 1E-4 and motif file JASPAR_CORE_2014_
VERTEBRATES.MEME from the Jaspar database (Mathelier et al., 2014).
For the unbiased discovery of motifs at TRIM33 enriched regions, 400 bp core sequences centered
around reproducible TRIM33 peaks were submitted to the browser-based MEME-ChIP analysis
(http://meme.nbcr.net/meme/tools/meme-chip).
CRISPR-Cas9 targeted deletion of Bim –117
The MSCV-hCas9-PGK-Puro construct was derived by cloning the N terminal 3× FLAG tag human-
codon optimized Cas9 cDNA (#49535; Addgene) into the MSCV-PGK-Puro vector (#634401;
Clontech). The U6-sgRNA-EFS-mCherry vector was constructed using the lentiviral backbone from
lentiCRISPR (#49535; Addgene). All sgRNAs were designed using http://crispr.mit.edu/ and cloned
into the U6-sgRNA-EFS-mCherry vector following published protocols (Ran et al., 2013). For sgRNA
lentivirus production, HEK293T cells were transfected with sgRNA:pVSVg:psPAX2 plasmids in a 4:2:3
ratio by using PEI reagent (#23966; Polysciences, Warrington, PA) following standard procedures. To
generate CRISPR competent line, parental B-ALL and 38B9 cells were transduced with MSCV-hCas9-
PGK-Puro construct followed by puromycin selection (1 μg/ml). To generate lines with a homozygous
deletion of Bim –117, two sgRNAs were designed to target flanking sequences of the −117 element
and were retrovirally co-transduced into B-ALL or 38B9 cells, followed by isolation of clonal lines by
limiting dilution. Genomic DNA was prepared from each clone using QiAamp DNA mini kit (#51304;
Qiagen) following the manufacturer’s instructions, followed by PCR-based screening for clones
harboring a homozygous deletion, using primers that span the Bim enhancer region. The −117
deletion of individual clones was further verified by Sanger sequencing. sgRNA and genotyping
primer sequences can be found in Supplementary file 2.
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Antibodies
Anti-TRIM33 antibody (A301-060A; Bethyl Laboratories, Montgomery, TX), Anti-PU.1 antibody
(#2266; Cell Signaling, Beverly, MA or sc-352; Santa Cruz, Dallas, TX), Anti-Bim antibody (#2819; Cell
Signaling), Anti-H3K27ac antibody (ab4729; Abcam, Cambridge, MA), Anti-H3K4me3 antibody (07-
473; Millipore), Anti-ß-actin HRP antibody (#A3854; Sigma, Ronkonkoma, NY), APC anti-mouse B220
(#103212; BioLegend, San Diego, CA), APC anti-mouse CD-19, APC anti-mouse Mac-1/Cd11b
(#101211; BioLegend), APC anti-mouse Ly-6G/Gr-1 (#17-5931; eBioscience, San Diego, CA), APC
anti-mouse TER-119 (#116212; BioLegend), APC anti-mouse CD-3 (#100209; BioLegend).
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